313 results on '"LAWS, ELIZABETH"'
Search Results
2. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
3. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
4. Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)
5. Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
6. Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
7. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
8. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
9. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
10. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
11. Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy
12. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
13. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
14. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
15. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
16. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
17. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
18. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
19. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
20. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
21. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
22. Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
23. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
24. Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
25. Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study
26. DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS.
27. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
28. A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic Duodenitis
29. Baseline Demographics And Disease Characteristics Of Pediatric Patients With Eosinophilic Esophagitis (EoE) From The Randomised, Placebo-Controlled, Phase 3 EoE KIDS Study
30. Dupilumab Normalized The Expression Of Genes Dysregulated In Eosinophilic Esophagitis (EoE) In Esophageal Biopsies From A Clinical Trial Of Children Aged 1–11 Years
31. Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS Trial
32. 507 - Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU
33. Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics
34. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL
35. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE NOTUS TRIAL
36. IN THE PHASE 3 BOREAS TRIAL, DUPILUMAB REDUCED FENO LEVELS OVER TIME IN PATIENTS WITH MODERATE OR SEVERE SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH TYPE 2 INFLAMMATION
37. IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL
38. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED BOREAS AND NOTUS RESULTS
39. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA
40. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma
41. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study
42. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study
43. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
44. Impact of Myeloid Reservoirs in HIV Cure Trials
45. S1876 An Adaptive Phase 2/3 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults and Adolescents With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
46. S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
47. S461 Dupilumab Efficacy in Eosinophilic Esophagitis Persists for Histologic, Symptomatic, and Endoscopic Outcomes Regardless of Concomitant High-Dose Proton Pump Inhibitor Use
48. EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
49. Dupilumab in Asia-Pacific patients with persistent asthma
50. Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.